BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233. [PMID: 9071937 DOI: 10.1136/gut.40.2.228] [Cited by in Crossref: 255] [Cited by in F6Publishing: 233] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Karatzoglou I, Yavropoulou MP, Pikilidou M, Germanidis G, Akriviadis E, Papazisi A, Daniilidis M, Zebekakis P, Yovos JG. Postprandial response of bone turnover markers in patients with Crohn’s disease. World J Gastroenterol 2014; 20(28): 9534-9540 [PMID: 25071349 DOI: 10.3748/wjg.v20.i28.9534] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Buchman AL. Metabolic bone disease in inflammatory bowel disease. Curr Treat Options Gastro 2002;5:173-80. [DOI: 10.1007/s11938-002-0039-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Cabré E, Gassull MA. Nutrition in inflammatory bowel disease: impact on disease and therapy: . Current Opinion in Gastroenterology 2001;17:342-9. [DOI: 10.1097/00001574-200107000-00008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
4 Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203-1208. [PMID: 11054377 DOI: 10.1053/gast.2000.19280] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 4.5] [Reference Citation Analysis]
5 Zhao X, Zhou C, Chen H, Ma J, Zhu Y, Wang P, Zhang Y, Ma H, Zhang H. Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. Medicine (Baltimore) 2017;96:e6378. [PMID: 28296781 DOI: 10.1097/MD.0000000000006378] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
6 Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:797-813. [PMID: 16917235 DOI: 10.1097/00054725-200608000-00016] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
7 Brounais-le Royer B, Pierroz DD, Velin D, Frossard C, Zheng XX, Lehr H, Ferrari-lacraz S, Ferrari SL. Effects of an Interleukin-15 Antagonist on Systemic and Skeletal Alterations in Mice with DSS-Induced Colitis. The American Journal of Pathology 2013;182:2155-67. [DOI: 10.1016/j.ajpath.2013.02.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Massironi S, Rossi RE, Cavalcoli FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr 2013;32:904-10. [PMID: 23602613 DOI: 10.1016/j.clnu.2013.03.020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
9 Harris L, Senagore P, Young VB, McCabe LR. Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice. Am J Physiol Gastrointest Liver Physiol 2009;296:G1020-9. [PMID: 19299577 DOI: 10.1152/ajpgi.90696.2008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
10 Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S. A Double-Blind Placebo-Controlled Study of Intravenous Clodronate for Prevention of Steroid-Induced Bone Loss in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2007;5:1184-9. [DOI: 10.1016/j.cgh.2007.05.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
11 Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol 2003;15:851-6. [PMID: 12867793 DOI: 10.1097/00042737-200308000-00003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
12 Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20:607-614. [PMID: 15352908 DOI: 10.1111/j.1365-2036.2004.02152.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
13 Poturoglu S, Balkan F, Karaali ZE, Ibrisim D, Yanmaz S, Aktuglu MB, Alioglu T, Kendir M. Relationship between bone mineral density and clinical features in patients with inflammatory bowel disease: a local study in Turkish population. J Int Med Res 2010;38:62-8. [PMID: 20233514 DOI: 10.1177/147323001003800107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
14 Miheller P, Muzes G, Hritz I, Lakatos G, Pregun I, Lakatos PL, Herszényi L, Tulassay Z. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn’s disease patients. Inflamm Bowel Dis. 2009;15:1656-1662. [PMID: 19408329 DOI: 10.1002/ibd.20947] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 7.6] [Reference Citation Analysis]
15 Narayanan SA, Metzger CE, Bloomfield SA, Zawieja DC. Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease. FASEB J 2018;32:4848-61. [PMID: 29596023 DOI: 10.1096/fj.201800178R] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
16 Lee N, Radford-Smith GL, Forwood M, Wong J, Taaffe DR. Body composition and muscle strength as predictors of bone mineral density in Crohn’s disease. J Bone Miner Metab. 2009;27:456-463. [PMID: 19333683 DOI: 10.1007/s00774-009-0059-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
17 Ciucci T, Ibáñez L, Boucoiran A, Birgy-Barelli E, Pène J, Abou-Ezzi G, Arab N, Rouleau M, Hébuterne X, Yssel H, Blin-Wakkach C, Wakkach A. Bone marrow Th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD. Gut 2015;64:1072-81. [PMID: 25298539 DOI: 10.1136/gutjnl-2014-306947] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 7.8] [Reference Citation Analysis]
18 Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841. [PMID: 12612917 DOI: 10.1053/gast.2003.50106] [Cited by in Crossref: 264] [Cited by in F6Publishing: 215] [Article Influence: 13.9] [Reference Citation Analysis]
19 van Hogezand RA, Bänffer D, Zwinderman AH, Mccloskey EV, Griffioen G, Hamdy NAT. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn’s disease. Osteoporos Int 2006;17:535-42. [DOI: 10.1007/s00198-005-0016-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
20 Wolf JL. Unmasking the Impact of Gender on Inflammatory Bowel Disease. Womens Health (Lond Engl) 2005;1:299-303. [DOI: 10.2217/17455057.1.3.299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Van staa T, Cooper C, Samuels Brusse L, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003;125:1591-7. [DOI: 10.1053/j.gastro.2003.09.027] [Cited by in Crossref: 174] [Cited by in F6Publishing: 148] [Article Influence: 9.2] [Reference Citation Analysis]
22 Buchman A, Moukarzel A. Metabolic bone disease associated with total parenteral nutrition. Clinical Nutrition 2000;19:217-31. [DOI: 10.1054/clnu.1999.0083] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
23 Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis. 1999;5:161-166. [PMID: 10453371 DOI: 10.1016/s0022-3476(99)70058-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
24 Yoon SY, Jung S. Nutritional Support in Patients with Inflammatory Bowel Diseases. Intest Res 2013;11:243. [DOI: 10.5217/ir.2013.11.4.243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Hamilton C, Seidner DL. Metabolic bone disease and parenteral nutrition. Curr Gastroenterol Rep 2004;6:335-41. [DOI: 10.1007/s11894-004-0087-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
26 Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001;48:473-7. [PMID: 11247890 DOI: 10.1136/gut.48.4.473] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
27 Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol 2004;38:218-24. [PMID: 15128066 DOI: 10.1097/00004836-200403000-00005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
28 Kim HJ, Hong SJ, Jeon YW, Han JP, Han SH, Kang JH, Tae JW, Lim HS, Kim HK, Ko BM. The early onset of disease may be a risk factor for decreased bone mineral density in patients with inflammatory bowel disease. Clin Endosc. 2013;46:71-76. [PMID: 23423611 DOI: 10.5946/ce.2013.46.1.71] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
29 Leder BZ, Kronenberg HM. Gastroenterologists and choosing the right bisphosphonate. Gastroenterology 2000;119:866-9. [DOI: 10.1053/gast.2000.17841] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
30 Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483-1490. [PMID: 9732930 DOI: 10.1111/j.1572-0241.1998.468_q.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 143] [Article Influence: 6.2] [Reference Citation Analysis]
31 Goh J, O'Morain CA. Review article: Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:307-320. [PMID: 12562443 DOI: 10.1046/j.1365-2036.2003.01482.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 127] [Article Influence: 7.7] [Reference Citation Analysis]
32 Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004;99:2178-85. [PMID: 15555000 DOI: 10.1111/j.1572-0241.2004.40071.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
33 Atreja A, Aggarwal A, Licata AA, Lashner BA. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal. 2012;2012:807438. [PMID: 22645457 DOI: 10.1100/2012/807438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
34 Szymczak-Tomczak A, Kaczmarek-Ryś M, Hryhorowicz S, Michalak M, Eder P, Skrzypczak-Zielińska M, Łykowska-Szuber L, Tomczak M, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Vitamin D, Vitamin D Receptor (VDR) Gene Polymorphisms (ApaI and FokI), and Bone Mineral Density in Patients With Inflammatory Bowel Disease. J Clin Densitom 2021;24:233-42. [PMID: 33172802 DOI: 10.1016/j.jocd.2020.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Stefanis N, Mackintosh C, Abraha HD, Treasure J, Moniz C. Dissociation of Bone Turnover in Anorexia Nervosa. Ann Clin Biochem 1998;35:709-16. [DOI: 10.1177/000456329803500602] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
36 Hoffmann P, Krisam J, Kasperk C, Gauss A. Prevalence, Risk Factors and Course of Osteoporosis in Patients with Crohn's Disease at a Tertiary Referral Center. J Clin Med 2019;8:E2178. [PMID: 31835600 DOI: 10.3390/jcm8122178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
37 Pironi L, Labate AM, Pertkiewicz M, Przedlacki J, Tjellesen L, Staun M, De Francesco A, Gallenca P, Guglielmi FW, Van Gossum A, Orlandoni P, Contaldo F, Villares JM;  Espen-Home Artificial Nutrition Working Group. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr. 2002;21:289-296. [PMID: 12135588 DOI: 10.1054/clnu.2002.0548] [Cited by in Crossref: 81] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
38 Tobias JH, Sasi MR, Greenwood R, Probert CSJ. Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy: RAPID BONE LOSS IN ACTIVE CROHN'S DISEASE. Alimentary Pharmacology & Therapeutics 2004;20:951-7. [DOI: 10.1111/j.1365-2036.2004.02207.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
39 Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259-265. [PMID: 20704624 DOI: 10.1111/j.1756-185x.2010.01542.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
40 Targownik LE, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol. 2014;30:168-174. [PMID: 24419292 DOI: 10.1097/mog.0000000000000037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 5.1] [Reference Citation Analysis]
41 Ulivieri FM, Lisciandrano D, Ranzi T, Taioli E, Cermesoni L, Piodi LP, Nava MC, Vezzoli M, Bianchi PA. Bone mineral density and body composition in patients with ulcerative colitis. Am J Gastroenterol 2000;95:1491-4. [PMID: 10894585 DOI: 10.1111/j.1572-0241.2000.02084.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
42 Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterology 2002;97:915-21. [DOI: 10.1111/j.1572-0241.2002.05609.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
43 Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15:857-864. [PMID: 12867794 DOI: 10.1097/00042737-200308000-00004] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 4.1] [Reference Citation Analysis]
44 Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, Srivastava AK, Warnick GR, Watts NB, Myers GL. Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline. Clinical Chemistry 2002;48:220-35. [DOI: 10.1093/clinchem/48.2.220] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
45 Radhakrishnan VM, Kojs P, Ramalingam R, Midura-Kiela MT, Angeli P, Kiela PR, Ghishan FK. Experimental colitis is associated with transcriptional inhibition of Na+/Ca2+ exchanger isoform 1 (NCX1) expression by interferon γ in the renal distal convoluted tubules. J Biol Chem 2015;290:8964-74. [PMID: 25648899 DOI: 10.1074/jbc.M114.616516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
46 Scheper HJ, Brand HS. Oral aspects of Crohn's disease. Int Dent J 2002;52:163-72. [PMID: 12090267 DOI: 10.1111/j.1875-595x.2002.tb00622.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
47 Irwin R, Lee T, Young VB, Parameswaran N, McCabe LR. Colitis-induced bone loss is gender dependent and associated with increased inflammation. Inflamm Bowel Dis. 2013;19:1586-1597. [PMID: 23702805 DOI: 10.1097/mib.0b013e318289e17b] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
48 van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl. 2006;59-64. [PMID: 16782623 DOI: 10.1080/00365520600664276] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
49 Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011;17:2122-2129. [PMID: 21910174 DOI: 10.1002/ibd.21601] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
50 Kuwabara A, Tanaka K, Tsugawa N, Nakase H, Tsuji H, Shide K, Kamao M, Chiba T, Inagaki N, Okano T, Kido S. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935-942. [PMID: 18825300 DOI: 10.1007/s00198-008-0764-2] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 5.4] [Reference Citation Analysis]
51 Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101:119-123. [PMID: 16405543 DOI: 10.1111/j.1572-0241.2006.00372.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
52 Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 2006;73:40-6. [PMID: 16543736 DOI: 10.1159/000092013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
53 Dear K, Compston J, Hunter J. Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clinical Nutrition 2001;20:541-6. [DOI: 10.1054/clnu.2001.0496] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
54 Sánchez Cano D, Ruiz-villaverde R, Olvera Porcel MC, Callejas Rubio JL, Pérez CC, García MG, Calvin JG, Centeno NO. Valoración de la densidad mineral ósea, marcadores de remodelado óseo, el sistema OPG/RANKL y el sTNF-RI en la enfermedad de Crohn. Gastroenterología y Hepatología 2011;34:3-9. [DOI: 10.1016/j.gastrohep.2010.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Shirazi KM, Somi MH, Rezaeifar P, Fattahi I, Khoshbaten M, Ahmadzadeh M. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol 2012;18:241-7. [PMID: 22824766 DOI: 10.4103/1319-3767.98428] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
56 Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465-473. [PMID: 15017646 DOI: 10.1016/s1542-3565(03)00185-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
57 Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol 2007; 13(46): 6156-6165 [PMID: 18069754 DOI: 10.3748/wjg.v13.i46.6156] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
58 Sinnott BP, Licata AA. Assessment of bone and mineral metabolism in inflammatory bowel disease: case series and review. Endocr Pract 2006;12:622-9. [PMID: 17229657 DOI: 10.4158/EP.12.6.622] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
59 Zali M, Bahari A, Firouzi F, Daryani NE, Aghazadeh R, Emam MM, Rezaie A, Shalmani HM, Naderi N, Maleki B. Bone mineral density in Iranian patients with inflammatory bowel disease. Int J Colorectal Dis. 2006;21:758-766. [PMID: 16463035 DOI: 10.1007/s00384-005-0084-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
60 Robinson RJ, Iqbal SJ, Abrams K, Al-Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther. 1998;12:699-705. [PMID: 9726381 DOI: 10.1046/j.1365-2036.1998.00364.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 2.3] [Reference Citation Analysis]
61 Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639-646. [PMID: 10982756 DOI: 10.1053/gast.2000.16518] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 5.5] [Reference Citation Analysis]
62 Nemetz A, Tóth M, García-González MA, Zágoni T, Fehér J, Peña AS, Tulassay Z. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 2001;49:644-9. [PMID: 11600466 DOI: 10.1136/gut.49.5.644] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
63 Nakajima S, Iijima H, Egawa S, Shinzaki S, Kondo J, Inoue T, Hayashi Y, Ying J, Mukai A, Akasaka T, Nishida T, Kanto T, Tsujii M, Hayashi N. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011;27:1023-8. [PMID: 21482072 DOI: 10.1016/j.nut.2010.10.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
64 Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol. 1997;32:1247-1255. [PMID: 9438324 DOI: 10.3109/00365529709028155] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 2.8] [Reference Citation Analysis]
65 Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A. Calcaneal ultrasound bone densitometry in inflammatory bowel disease--a comparison with double x-ray densitometry of the lumbar spine. Am J Gastroenterol 1998;93:2339-44. [PMID: 9860389 DOI: 10.1111/j.1572-0241.1998.00685.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
66 Khan ZAW, Shetty S, Pai GC, Acharya KKV, Nagaraja R. Prevalence of low bone mineral density in inflammatory bowel disease and factors associated with it. Indian J Gastroenterol 2020;39:346-53. [PMID: 32940845 DOI: 10.1007/s12664-020-01048-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Głąbska D, Guzek D, Kanarek B, Lech G. Analysis of Association Between Dietary Intake and Red Blood Cell Count Results in Remission Ulcerative Colitis Individuals. Medicina (Kaunas) 2019;55:E96. [PMID: 30965640 DOI: 10.3390/medicina55040096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Gassull MA, Cabré E. Nutrition in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2001;4:561-9. [PMID: 11706295 DOI: 10.1097/00075197-200111000-00018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
69 Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther. 2003;18:1121-1127. [PMID: 14653832 DOI: 10.1111/j.1365-2036.2003.01794.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
70 Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019;53:441-448. [PMID: 29672437 DOI: 10.1097/mcg.0000000000001031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
71 Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Seinhart H, Greenberg G. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis. 2004;10:220-228. [PMID: 15290915 DOI: 10.1097/00054725-200405000-00007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
72 Hashash JG, Binion DG. Exercise and Inflammatory Bowel Disease: Insights into Etiopathogenesis and Modification of Clinical Course. Gastroenterol Clin North Am 2017;46:895-905. [PMID: 29173530 DOI: 10.1016/j.gtc.2017.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
73 Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54:479-487. [PMID: 15753532 DOI: 10.1136/gut.2004.044370] [Cited by in Crossref: 156] [Cited by in F6Publishing: 132] [Article Influence: 9.2] [Reference Citation Analysis]
74 Legido J, Gisbert JP, Maté J. Alteraciones del metabolismo óseo en 100 pacientes con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2011;34:379-84. [DOI: 10.1016/j.gastrohep.2011.03.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
75 Wada Y, Hisamatsu T, Naganuma M, Matsuoka K, Okamoto S, Inoue N, Yajima T, Kouyama K, Iwao Y, Ogata H, Hibi T, Abe T, Kanai T. Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. Clin Nutr. 2015;34:1202-1209. [PMID: 25618799 DOI: 10.1016/j.clnu.2015.01.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
76 Pluskiewicz W, Zdrzałek J, Karasek D. Spine bone mineral density and VDR polymorphism in subjects with ulcerative colitis. J Bone Miner Metab 2009;27:567-73. [DOI: 10.1007/s00774-009-0072-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
77 Schwartz DA, Connolley CD, Koyama T, Wise PE, Herline AJ. Calcaneal Ultrasound Bone Densitometry Is Not a Useful Tool to Screen Patients With Inflammatory Bowel Disease at High Risk for Metabolic Bone Disease: . Inflammatory Bowel Diseases 2005;11:749-54. [DOI: 10.1097/01.mib.0000172809.11501.f4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Lopes LH, Sdepanian VL, Szejnfeld VL, de Morais MB, Fagundes-Neto U. Risk factors for low bone mineral density in children and adolescents with inflammatory bowel disease. Dig Dis Sci. 2008;53:2746-2753. [PMID: 18351466 DOI: 10.1007/s10620-008-0223-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
79 Cohen SL, Moore AM, Ward WE. Interleukin-10 Knockout Mouse:: A Model for Studying Bone Metabolism During Intestinal Inflammation. Inflammatory Bowel Diseases 2004;10:557-63. [DOI: 10.1097/00054725-200409000-00009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
80 Bremner AR, Griffiths DM, Beattie RM. Current therapy of ulcerative colitis in children. Expert Opin Pharmacother 2004;5:37-53. [PMID: 14680434 DOI: 10.1517/14656566.5.1.37] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
81 Becker C. Clinical evaluation for osteoporosis. Clin Geriatr Med 2003;19:299-320. [PMID: 12916288 DOI: 10.1016/s0749-0690(02)00068-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
82 Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475. [PMID: 12145800 DOI: 10.1053/gast.2002.34779] [Cited by in Crossref: 122] [Cited by in F6Publishing: 99] [Article Influence: 6.1] [Reference Citation Analysis]
83 Roux C, Abitbol V, Chaussade S, Dougados M. Ostéoporose des entérocolopathies. Revue du Rhumatisme 2001;68:736-41. [DOI: 10.1016/s1169-8330(01)00180-6] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
84 Shahidi N, Bressler B, Panaccione R. Vedolizumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 2015;16:129-35. [DOI: 10.1517/14712598.2016.1121231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Robinson RJ, al-Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998;43:2500-6. [PMID: 9824142 DOI: 10.1023/a:1026650719552] [Cited by in Crossref: 85] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
86 Lima CA, Lyra AC, Mendes CMC, Lopes MB, Coqueiro FG, Rocha R, Santana GO. Bone mineral density and inflammatory bowel disease severity. Braz J Med Biol Res. 2017;50:e6374. [PMID: 29069227 DOI: 10.1590/1414-431x20176374] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
87 Szpalski M, Gunzburg R. What are the advances for surgical therapy of inflammatory diseases of the spine? Best Practice & Research Clinical Rheumatology 2002;16:141-54. [DOI: 10.1053/berh.2001.0211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
88 Mauro M, Armstrong D. Evaluation of densitometric bone-muscle relationships in Crohn’s disease. Bone. 2007;40:1610-1614. [PMID: 17433801 DOI: 10.1016/j.bone.2007.02.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
89 Guo Z, Wu R, Gong J, Zhu W, Li Y, Li N, Li J. The efficacy and safety of bisphosphonates for osteoporosis or osteopenia in Crohn's disease: a meta-analysis. Dig Dis Sci 2013;58:915-22. [PMID: 23179146 DOI: 10.1007/s10620-012-2465-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
90 Soare I, Sirbu A, Martin S, Diculescu M, Mateescu B, Tieranu C, Fica S. Assessment of bone quality with trabecular bone score in patients with inflammatory bowel disease. Sci Rep 2021;11:20345. [PMID: 34645875 DOI: 10.1038/s41598-021-99669-z] [Reference Citation Analysis]
91 Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn's disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013;19:1173-1178. [PMID: 23511037 DOI: 10.1097/mib.0b013e31828075a7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
92 Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis. 2006;24:201-206. [PMID: 16699279 DOI: 10.1159/000091299] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
93 Lora FL, Amarante HM, Pisani JC, Borba VV, Kulak CA, Carmes ER. [Bone mineral density evaluation in inflammatory bowel disease patients]. Arq Gastroenterol 2005;42:201-5. [PMID: 16444373 DOI: 10.1590/s0004-28032005000400003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Lucendo AJ, De Rezende LC. Importance of nutrition in inflammatory bowel disease. World J Gastroenterol. 2009;15:2081-2088. [PMID: 19418580 DOI: 10.3748/wjg.15.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Vernia P, Loizos P, Di Giuseppantonio I, Amore B, Chiappini A, Cannizzaro S. Dietary calcium intake in patients with inflammatory bowel disease. J Crohns Colitis. 2014;8:312-317. [PMID: 24090907 DOI: 10.1016/j.crohns.2013.09.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
96 Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, Boyen GBV, Tirpitz CV. Bones and Crohn’s: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol 2011; 17(3): 334-342 [PMID: 21253392 DOI: 10.3748/wjg.v17.i3.334] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
97 Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease? The Lancet 2001;357:1995-6. [DOI: 10.1016/s0140-6736(00)05135-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
98 Veerappan SG, Healy M, Walsh BJ, O'Morain CA, Daly JS, Ryan BM. Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease. Dig Dis Sci. 2015;60:2119-2129. [PMID: 25732718 DOI: 10.1007/s10620-015-3606-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
99 Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55-63. [PMID: 16340635 DOI: 10.1097/01.mcg.0000190762.80615.d4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
100 Niv Y, Dickman R, Levi Z, Neumann G, Ehrlich D, Bitterman H, Dreiher J, Cohen A, Comaneshter D, Halpern E. Establishing an integrated gastroenterology service between a medical center and the community. World J Gastroenterol 2015; 21(7): 2152-2158 [PMID: 25717251 DOI: 10.3748/wjg.v21.i7.2152] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
101 Abitbol V, Mary JY, Roux C, Soulé JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S; Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002;16:919-27. [PMID: 11966500 DOI: 10.1046/j.1365-2036.2002.01247.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
102 Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1895-1902. [PMID: 12390098 DOI: 10.1046/j.1365-2036.2002.01363.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
103 Héla S, Nihel M, Faten L, Monia F, Jalel B, Azza F, Slaheddine S. Osteoporosis and Crohn's disease. Joint Bone Spine 2005;72:403-7. [PMID: 16112594 DOI: 10.1016/j.jbspin.2004.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
104 Orlic ZC, Turk T, Sincic BM, Stimac D, Cvijanovic O, Maric I, Tomas MI, Jurisic-Erzen D, Licul V, Bobinac D. How activity of inflammatory bowel disease influences bone loss. J Clin Densitom 2010;13:36-42. [PMID: 20171567 DOI: 10.1016/j.jocd.2009.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
105 Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12(30): 4819-4831 [PMID: 16937463 DOI: 10.3748/wjg.v12.i30.4819] [Cited by in CrossRef: 175] [Cited by in F6Publishing: 147] [Article Influence: 10.9] [Reference Citation Analysis]
106 Cashman KD. Altered bone metabolism in inflammatory disease: role for nutrition: Symposium on ‘Diet and bone health’. Proc Nutr Soc 2008;67:196-205. [DOI: 10.1017/s0029665108007039] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
107 Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. Pharmacoeconomics 2008;26:311-28. [PMID: 18370566 DOI: 10.2165/00019053-200826040-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
108 von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003;17:807-16. [PMID: 12641503 DOI: 10.1046/j.1365-2036.2003.01448.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
109 Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis. 2006;12:1162-1174. [PMID: 17119391 DOI: 10.1097/01.mib.0000236929.74040.b0] [Cited by in Crossref: 110] [Cited by in F6Publishing: 91] [Article Influence: 7.3] [Reference Citation Analysis]
110 Tran DN, Go SM, Park SM, Jung EM, Jeung EB. Loss of Nckx3 Exacerbates Experimental DSS-Induced Colitis in Mice through p53/NF-κB Pathway. Int J Mol Sci 2021;22:2645. [PMID: 33807999 DOI: 10.3390/ijms22052645] [Reference Citation Analysis]
111 Lee N, Fowler E, Mason S, Lincoln D, Taaffe DR, Radford-smith G. Tumor necrosis factor-? haplotype is strongly associated with bone mineral density in patients with Crohn's disease. J Gastroenterol Hepatol 2007;22:913-9. [DOI: 10.1111/j.1440-1746.2006.04679.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
112 Bjarnason I. Metabolic bone disease in patients with inflammatory bowel disease. Rheumatology (Oxford) 1999;38:801-4. [PMID: 10515637 DOI: 10.1093/rheumatology/38.9.801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
113 Stockbrügger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, Felsenberg D, Ljunghall S, Nygard G, Persson T. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther. 2002;16:1519-1527. [PMID: 12182752 DOI: 10.1046/j.1365-2036.2002.01317.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
114 Bernstein CN, Leslie WD. Osteoporosis and inflammatory bowel disease: REVIEW: OSTEOPOROSIS AND INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2004;19:941-52. [DOI: 10.1111/j.1365-2036.2004.01876.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
115 Krok KL, Lichtenstein GR. Nutrition in Crohn disease: . Current Opinion in Gastroenterology 2003;19:148-53. [DOI: 10.1097/00001574-200303000-00009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
116 Metzger CE, Narayanan SA, Elizondo JP, Carter AM, Zawieja DC, Hogan HA, Bloomfield SA. DSS-induced colitis produces inflammation-induced bone loss while irisin treatment mitigates the inflammatory state in both gut and bone. Sci Rep 2019;9:15144. [PMID: 31641205 DOI: 10.1038/s41598-019-51550-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
117 Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A. Evolution of Osteopenia in Inflammatory Bowel Disease. American Journal of Gastroenterology 1999;94:1292-7. [DOI: 10.1111/j.1572-0241.1999.01079.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 70] [Article Influence: 3.7] [Reference Citation Analysis]
118 Schoon EJ, Geerling BG, Van Dooren IM, Schurgers LJ, Vermeer C, Brummer RJ, Stockbrügger RW. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol Ther 2001;15:783-92. [PMID: 11380316 DOI: 10.1046/j.1365-2036.2001.00997.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
119 Collins FL, Schepper JD, Rios-Arce ND, Steury MD, Kang HJ, Mallin H, Schoenherr D, Camfield G, Chishti S, McCabe LR, Parameswaran N. Immunology of Gut-Bone Signaling. Adv Exp Med Biol 2017;1033:59-94. [PMID: 29101652 DOI: 10.1007/978-3-319-66653-2_5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
120 Iijima H, Shinzaki S, Takehara T. The importance of vitamins D and K for the bone health and immune function in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2012;15:635-640. [PMID: 22914505 DOI: 10.1097/mco.0b013e328357f623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
121 Tsai MS, Lin CL, Tu YK, Lee PH, Kao CH. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69:235-241. [PMID: 25472555 DOI: 10.1111/ijcp.12526] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
122 Gilman J, Cashman KD. The effect of marine oil-derived n -3 fatty acids on transepithelial calcium transport in Caco-2 cell models of healthy and inflamed intestines. Br J Nutr 2007;97:281-8. [DOI: 10.1017/s0007114507201758] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Roblin X, Phelip JM, Genevois M, Ducros V, Bonaz B. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn’s disease: HYPERHOMOCYSTEINAEMIA IN PATIENTS WITH CROHN’S DISEASE. Alimentary Pharmacology & Therapeutics 2007;25:797-804. [DOI: 10.1111/j.1365-2036.2007.03260.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
124 Donnellan CF, Yann LH, Lal S. Nutritional management of Crohn’s disease. Therap Adv Gastroenterol. 2013;6:231-242. [PMID: 23634187 DOI: 10.1177/1756283x13477715] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
125 Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med. 2010;42:97-114. [PMID: 20166813 DOI: 10.3109/07853890903559724] [Cited by in Crossref: 172] [Cited by in F6Publishing: 148] [Article Influence: 14.3] [Reference Citation Analysis]
126 Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. 2000;46 Suppl 1:i1-i8. [PMID: 10647595 DOI: 10.1136/gut.46.suppl_1.i1] [Cited by in Crossref: 142] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
127 Robertson DJ, Grimm IS. INFLAMMATORY BOWEL DISEASE IN THE ELDERLY. Gastroenterology Clinics of North America 2001;30:409-26. [DOI: 10.1016/s0889-8553(05)70188-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
128 Oostlander AE, Bravenboer N, Sohl E, Holzmann PJ, van der Woude CJ, Dijkstra G, Stokkers PC, Oldenburg B, Netelenbos JC, Hommes DW, van Bodegraven AA, Lips P. Histomorphometric Analysis Reveals Reduced Bone Mass and Bone Formation in Patients With Quiescent Crohn's Disease. Gastroenterology 2011;140:116-23. [DOI: 10.1053/j.gastro.2010.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
129 Walldorf J, Krummenerl A, Engler K, Busch J, Dollinger MM, Seufferlein T, Albert JG. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis. 2013;7:901-907. [PMID: 23333038 DOI: 10.1016/j.crohns.2012.12.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
130 Compston JE. Can biochemical markers be used to screen patients with inflammatory bowel disease for osteoporosis?: . European Journal of Gastroenterology & Hepatology 2002;14:587-9. [DOI: 10.1097/00042737-200206000-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
131 Klaus J, Armbrecht G, Steinkamp M, Brückel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002;51:654-8. [PMID: 12377802 DOI: 10.1136/gut.51.5.654] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 6.5] [Reference Citation Analysis]
132 Orlic ZC, Raisz LG. Causes of Secondary Osteoporosis. Journal of Clinical Densitometry 1999;2:79-92. [DOI: 10.1385/jcd:2:1:79] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
133 Kochar B, Orkaby AR, Ananthakrishnan AN, Ritchie CS. Frailty in inflammatory bowel diseases: an emerging concept. Therap Adv Gastroenterol 2021;14:17562848211025474. [PMID: 34594400 DOI: 10.1177/17562848211025474] [Reference Citation Analysis]
134 Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol. 1999;94:824-828. [PMID: 10086673 DOI: 10.1111/j.1572-0241.1999.00866.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 2.6] [Reference Citation Analysis]
135 Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007;5:721-8. [PMID: 17482522 DOI: 10.1016/j.cgh.2007.02.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
136 Huybers S, Apostolaki M, van der Eerden BCJ, Kollias G, Naber THJ, Bindels RJM, Hoenderop JGJ. Murine TNFΔARE Crohnʼs disease model displays diminished expression of intestinal Ca2+ transporters: . Inflammatory Bowel Diseases 2008;14:803-11. [DOI: 10.1002/ibd.20385] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
137 Zakaria AA, Rifat SF. Inflammatory Bowel Disease: Concerns for the Athlete. Current Sports Medicine Reports 2008;7:104-7. [DOI: 10.1097/01.csmr.0000313398.94816.47] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1267-1273. [PMID: 14624148 DOI: 10.1097/00042737-200312000-00003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
139 Schulte CM, Dignass AU, Goebell H, Röher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909-920. [PMID: 11040178 DOI: 10.1053/gast.2000.18158] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 3.9] [Reference Citation Analysis]
140 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
141 Schulte C, Dignass AU, Mann K, Goebell H. Reduced Bone Mineral Density and Unbalanced Bone Metabolism in Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1998;4:268-75. [DOI: 10.1097/00054725-199811000-00002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
142 Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:225-32. [DOI: 10.1007/s11894-003-0024-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
143 Graham TO, Kandil HM. Nutritional factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:203-18. [PMID: 12122732 DOI: 10.1016/s0889-8553(01)00022-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
144 Garcia-planella E, Domènech E. Osteopenia y osteoporosis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2004;27:417-24. [DOI: 10.1016/s0210-5705(03)70491-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
145 Stobaugh DJ, Deepak P, Ehrenpreis ED. Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome. Osteoporos Int 2013;24:1169-75. [DOI: 10.1007/s00198-012-2141-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
146 Hilmi I, Sunderesvaran K, Ananda V, Sarji SA, Arumugam K, Goh KL. Increased fracture risk and osteoporosis not associated with vitamin D levels in Malaysian patients with inflammatory bowel disease. J Clin Endocrinol Metab. 2013;98:2415-2421. [PMID: 23553858 DOI: 10.1210/jc.2013-1147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
147 Gilman J, Shanahan F, Cashman KD. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2006;23:1007-16. [DOI: 10.1111/j.1365-2036.2006.02835.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
148 Wagner IJ, Rombeau JL. Nutritional support of surgical patients with inflammatory bowel disease. Surg Clin North Am. 2011;91:787-803, viii. [PMID: 21787968 DOI: 10.1016/j.suc.2011.04.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
149 Southerland JC, Valentine JF. Osteopenia and osteoporosis in gastrointestinal diseases: Diagnosis and treatment. Curr Gastroenterol Rep 2001;3:399-407. [DOI: 10.1007/s11894-001-0082-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
150 Metzger CE, Narayanan A, Zawieja DC, Bloomfield SA. Inflammatory Bowel Disease in a Rodent Model Alters Osteocyte Protein Levels Controlling Bone Turnover: IBD IN RODENT MODEL ALTERS OSTEOCYTE PROTEIN CONTROLLING BONE TURNOVER. J Bone Miner Res 2017;32:802-13. [DOI: 10.1002/jbmr.3027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
151 Sgambato D, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, Miranda A, De Mauro D, Romano L, Iolascon G, Romano M. Bone alterations in inflammatory bowel diseases. World J Clin Cases 2019; 7(15): 1908-1925 [PMID: 31423424 DOI: 10.12998/wjcc.v7.i15.1908] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
152 Chin KY, Ima-Nirwana S. Olives and Bone: A Green Osteoporosis Prevention Option. Int J Environ Res Public Health. 2016;13. [PMID: 27472350 DOI: 10.3390/ijerph13080755] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
153 Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis. 2002;8:87-92. [PMID: 11854605 DOI: 10.1097/00054725-200203000-00003] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 4.1] [Reference Citation Analysis]
154 Sylvester FA, Davis PM, Wyzga N, Hyams JS, Lerer T. Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr 2006;148:461-6. [PMID: 16647405 DOI: 10.1016/j.jpeds.2005.12.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
155 Souza HN, Lora FL, Kulak CA, Mañas NC, Amarante HM, Borba VZ. [Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density]. Arq Bras Endocrinol Metabol 2008;52:684-91. [PMID: 18604382 DOI: 10.1590/s0004-27302008000400015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
156 Targownik LE, Bernstein CN, Nugent Z, Leslie WD. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013;11:278-285. [PMID: 23103821 DOI: 10.1016/j.cgh.2012.10.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
157 Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology. 1998;115:36-41. [PMID: 9649456 DOI: 10.1016/s0016-5085(98)70362-2] [Cited by in Crossref: 98] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
158 Sugimoto K, Ikeya K, Iida T, Kawasaki S, Arai O, Umehara K, Watanabe F, Tani S, Oishi S, Osawa S, Yamamoto T, Hanai H. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease. Dig Dis Sci 2016;61:99-106. [PMID: 26254083 DOI: 10.1007/s10620-015-3838-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
159 Shen B, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, Skugor M, Bennett AE, Brzezinski A, Queener E. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104:639-646. [PMID: 19262520 DOI: 10.1038/ajg.2008.78] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
160 Klaus J, Reinshagen M, Adler G, Boehm B, von Tirpitz C. Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density. BMC Gastroenterol 2008;8:48. [PMID: 18947388 DOI: 10.1186/1471-230X-8-48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
161 Ismail MH, Al-Elq AH, Al-Jarodi ME, Azzam NA, Aljebreen AM, Al-Momen SA, Bseiso BF, Al-Mulhim FA, Alquorain A. Frequency of low bone mineral density in Saudi patients with inflammatory bowel disease. Saudi J Gastroenterol. 2012;18:201-207. [PMID: 22626800 DOI: 10.4103/1319-3767.96458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
162 Trebble TM, Arden NK, Wootton SA, Calder PC, Mullee MA, Fine DR, Stroud MA. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. The American Journal of Clinical Nutrition 2004;80:1137-44. [DOI: 10.1093/ajcn/80.5.1137] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
163 Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2011;300:G191-G201. [PMID: 21088237 DOI: 10.1152/ajpgi.00496.2010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
164 Maldonado FJ, Al Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, Mccollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2019;25:1072-9. [DOI: 10.1093/ibd/izy341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
165 Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab155. [PMID: 34279600 DOI: 10.1093/ibd/izab155] [Reference Citation Analysis]
166 Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
167 Miller KK. Mechanisms by Which Nutritional Disorders Cause Reduced Bone Mass in Adults. Journal of Women's Health 2003;12:145-50. [DOI: 10.1089/154099903321576538] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
168 Ahn HJ, Kim YJ, Lee HS, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Kim BJ, Park SH. High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00690-X. [PMID: 34216823 DOI: 10.1016/j.cgh.2021.06.026] [Reference Citation Analysis]
169 Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn’s disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005;11:1108-1118. [PMID: 16306774 DOI: 10.1097/01.mib.0000192325.28168.08] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
170 Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohns Colitis. 2008;2:202-207. [PMID: 21172211 DOI: 10.1016/j.crohns.2008.01.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
171 Mauro M, Armstrong D. Juvenile onset of Crohn's disease: A risk factor for reduced lumbar bone mass in premenopausal women. Bone 2007;40:1290-3. [DOI: 10.1016/j.bone.2007.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
172 Miranda-Bautista J, Verdejo C, Díaz-Redondo A, Bretón I, Bellón JM, Pérez-Valderas MD, Caballero-Marcos A, de Dios-Lascuevas M, González-Río E, García-Sánchez C, Marín-Jiménez I, Bañares R, Menchén L. Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain. Therap Adv Gastroenterol 2019;12:1756284819862152. [PMID: 31391867 DOI: 10.1177/1756284819862152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
173 Watters C, Wright SJ, Robinson RJ, Krzywicki T, Almond L, Shevlin M, Mayberry JF. Positive and negative wellbeing as predictors of exercise uptake in Crohn's disease: An exploratory study. Psychology, Health & Medicine 2010;6:293-9. [DOI: 10.1080/13548500123365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
174 Van Schaik FD, Verhagen MA, Siersema PD, Oldenburg B. High prevalence of low bone mineral density in patients with Inflammatory Bowel Disease in the setting of a peripheral Dutch hospital. Journal of Crohn's and Colitis 2008;2:208-13. [DOI: 10.1016/j.crohns.2008.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
175 Ouahed J, Gordon W, Canavan JB, Zhou H, Du S, von Schack D, Phillips K, Wang L, Dunn WA 3rd, Field M, Friel S, Griffith A, Evans S, Tollefson S, Carrellas M, Cao B, Merker A, Bousvaros A, Shouval DS, Hung K, Lepsy C, Afzelius L, Korzenik JR, Snapper SB; BCH IBD Center., BWH Crohn’s and Colitis Center. Mucosal Gene Expression in Pediatric and Adult Patients With Ulcerative Colitis Permits Modeling of Ideal Biopsy Collection Strategy for Transcriptomic Analysis. Inflamm Bowel Dis 2018;24:2565-78. [PMID: 30085215 DOI: 10.1093/ibd/izy242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
176 de Jong DJ, Corstens FH, Mannaerts L, van Rossum LG, Naber AH. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol 2002;97:2011-5. [PMID: 12190169 DOI: 10.1111/j.1572-0241.2002.05916.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
177 Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000;247:63-70. [DOI: 10.1046/j.1365-2796.2000.00582.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 115] [Article Influence: 5.9] [Reference Citation Analysis]
178 Radhakrishnan VM, Gilpatrick MM, Parsa NA, Kiela PR, Ghishan FK. Expression of Cav1.3 calcium channel in the human and mouse colon: posttranscriptional inhibition by IFNγ. Am J Physiol Gastrointest Liver Physiol 2017;312:G77-84. [PMID: 27932504 DOI: 10.1152/ajpgi.00394.2016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
179 Noble CL, McCullough J, Ho W, Lees CW, Nimmo E, Drummond H, Bear S, Hannan J, Millar C, Ralston SH. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:588-596. [PMID: 18194505 DOI: 10.1111/j.1365-2036.2008.03599.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
180 Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore) 2017;96:e6788. [PMID: 28562531 DOI: 10.1097/MD.0000000000006788] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
181 Huybers S, Naber TH, Bindels RJ, Hoenderop JG. Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol. 2007;292:G92-G97. [PMID: 16901990 DOI: 10.1152/ajpgi.00317.2006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
182 Klaus J, Haenle MM, Schröter C, Adler G, von Boyen G, Reinshagen M, von Tirpitz C. A Single Dose of Intravenous Zoledronate Prevents Glucocorticoid Therapy-Associated Bone Loss in Acute Flare of Crohn's Disease, a Randomized Controlled Trial. American Journal of Gastroenterology 2011;106:786-93. [DOI: 10.1038/ajg.2011.59] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
183 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 30.1] [Reference Citation Analysis]
184 Nguyen DL, Limketkai B, Medici V, Saire Mendoza M, Palmer L, Bechtold M. Nutritional Strategies in the Management of Adult Patients with Inflammatory Bowel Disease: Dietary Considerations from Active Disease to Disease Remission. Curr Gastroenterol Rep 2016;18:55. [PMID: 27637649 DOI: 10.1007/s11894-016-0527-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
185 Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol 2006; 12(35): 5680-5686 [PMID: 17007022 DOI: 10.3748/wjg.v12.i35.5680] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
186 Vázquez MA, Lopez E, Montoya MJ, Giner M, Pérez-Temprano R, Pérez-Cano R. Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol 2012;12:47. [PMID: 22584049 DOI: 10.1186/1471-230X-12-47] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
187 Whitten KE, Leach ST, Bohane TD, Woodhead HJ, Day AS. Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. J Gastroenterol. 2010;45:399-405. [PMID: 19957194 DOI: 10.1007/s00535-009-0165-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
188 Buchman AL. Bones and Crohn's: problems and solutions. Inflamm Bowel Dis. 1999;5:212-227. [PMID: 10453378 DOI: 10.1097/00054725-199908000-00010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
189 Papaioannou A, Ferko NC, Adachi JD. All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Pro: . Inflammatory Bowel Diseases 2001;7:158-62. [DOI: 10.1097/00054725-200105000-00012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
190 Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:878-883. [PMID: 10201450 DOI: 10.1111/j.1572-0241.1999.981_d.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 3.2] [Reference Citation Analysis]
191 Lucendo AJ, De Rezende LC. Importance of nutrition in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2081-2088 [PMID: 19418580 DOI: 10.3748/wjg.15.2081] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
192 Miheller P, Muzes G, Rácz K, Blázovits A, Lakatos P, Herszényi L, Tulassay Z. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13:1379-1384. [PMID: 17663430 DOI: 10.1002/ibd.20234] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
193 Miheller P, Lőrinczy K, Lakatos PL. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol 2010; 16(44): 5536-5542 [PMID: 21105186 DOI: 10.3748/wjg.v16.i44.5536] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
194 Gupta S, Shen B. Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease. Gastroenterol Rep (Oxf). 2013;1:159-165. [PMID: 24759961 DOI: 10.1093/gastro/got030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
195 Kitazaki S, Mitsuyama K, Masuda J, Harada K, Yamasaki H, Kuwaki K, Takedatsu H, Sugiyama G, Tsuruta O, Sata M. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. Aliment Pharmacol Ther. 2009;29:424-430. [PMID: 19035979 DOI: 10.1111/j.1365-2036.2008.03899.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
196 Ewid M, Al Mutiri N, Al Omar K, Shamsan AN, Rathore AA, Saquib N, Salaas A, Al Sarraj O, Nasri Y, Attal A, Tawfiq A, Sherif H. Updated bone mineral density status in Saudi patients with inflammatory bowel disease. World J Gastroenterol 2020; 26(35): 5343-5353 [PMID: 32994692 DOI: 10.3748/wjg.v26.i35.5343] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Haschka J, Hirschmann S, Kleyer A, Englbrecht M, Faustini F, Simon D, Figueiredo CP, Schuster L, Muschitz C, Kocijan R, Resch H, Atreya R, Rech J, Neurath MF, Schett G. High-resolution Quantitative Computed Tomography Demonstrates Structural Defects in Cortical and Trabecular Bone in IBD Patients. J Crohns Colitis 2016;10:532-40. [PMID: 26818661 DOI: 10.1093/ecco-jcc/jjw012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
198 Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:699-704. [PMID: 10710060 DOI: 10.1111/j.1572-0241.2000.01850.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
199 Irwin R, Raehtz S, Parameswaran N, McCabe LR. Intestinal inflammation without weight loss decreases bone density and growth. Am J Physiol Regul Integr Comp Physiol 2016;311:R1149-57. [PMID: 27733383 DOI: 10.1152/ajpregu.00051.2016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
200 De Vos M, De Keyser F, Mielants H, Cuvelier C, Veys E. Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:397-404. [PMID: 9663718 DOI: 10.1046/j.1365-2036.1998.00325.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
201 Oh HJ, Ryu KH, Park BJ, Yoon BH. Osteoporosis and Osteoporotic Fractures in Gastrointestinal Disease. J Bone Metab 2018;25:213-7. [PMID: 30574465 DOI: 10.11005/jbm.2018.25.4.213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
202 Bregenzer N, Erban P, Albrich H, Schmitz G, Feuerbach S, Schölmerich J, Andus T. Screening for osteoporosis in patients with inflammatory bowel disease by using urinary N-telopeptides: . European Journal of Gastroenterology & Hepatology 2002;14:599-605. [DOI: 10.1097/00042737-200206000-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
203 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
204 Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol. 2007;23:400-405. [PMID: 17545776 DOI: 10.1097/mog.0b013e3281ddb2a3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
205 Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595. [PMID: 23835489 DOI: 10.1038/nrgastro.2013.117] [Cited by in Crossref: 124] [Cited by in F6Publishing: 115] [Article Influence: 13.8] [Reference Citation Analysis]
206 Dresner-Pollak R, Gelb N, Rachmilewitz D, Karmeli F, Weinreb M. Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology 2004;127:792-801. [PMID: 15362035 DOI: 10.1053/j.gastro.2004.06.013] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 5.7] [Reference Citation Analysis]
207 Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K, Hawker G, Griffiths AM. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:42-50. [PMID: 17206638 DOI: 10.1002/ibd.20006] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 7.6] [Reference Citation Analysis]
208 Rosenfeld G, Parker CE, MacDonald JK, Bressler B. Etrolizumab for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;:CD011661. [PMID: 26630451 DOI: 10.1002/14651858.CD011661.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Reyes García R, Jódar Gimeno E, García Martín A, Romero Muñoz M, Gómez Sáez JM, Luque Fernández I, Varsavsky M, Guadalix Iglesias S, Cano Rodriguez I, Ballesteros Pomar MD, Vidal Casariego A, Rozas Moreno P, Cortés Berdonces M, Fernández García D, Calleja Canelas A, Palma Moya M, Martínez Díaz-guerra G, Jimenez Moleón JJ, Muñoz Torres M. Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales. Endocrinología y Nutrición 2012;59:174-96. [DOI: 10.1016/j.endonu.2012.01.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
210 Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Haptén-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbrügger RW; Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:113-21. [PMID: 15704045 DOI: 10.1016/s1542-3565(04)00662-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
211 Wild GE, Drozdowski L, Tartaglia C, Clandinin MT, Thomson AB. Nutritional modulation of the inflammatory response in inflammatory bowel disease- From the molecular to the integrative to the clinical. World J Gastroenterol 2007; 13(1): 1-7 [PMID: 17206749 DOI: 10.3748/wjg.v13.i1.1] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
212 Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol 2007;21:637-42. [PMID: 17948133 DOI: 10.1155/2007/216162] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
213 Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn’s disease. Clinical Gastroenterology and Hepatology 2005;3:122-32. [DOI: 10.1016/s1542-3565(04)00663-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
214 Sakellariou GT, Moschos J, Berberidis C, Mpoumponaris A, Kadis S, Molyvas E, Kouklakis G. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine. 2006;73:725-728. [PMID: 17126059 DOI: 10.1016/j.jbspin.2006.01.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
215 McCarthy D, Duggan P, O’Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Seasonality of vitamin D status and bone turnover in patients with Crohn’s disease. Aliment Pharmacol Ther. 2005;21:1073-1083. [PMID: 15854168 DOI: 10.1111/j.1365-2036.2005.02446.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 3.9] [Reference Citation Analysis]
216 Aljarallah B, Fernandes G, Jeejeebhoy KN, Gramlich LM, Whittaker JS, Armstrong D, Duerksen DR, Allard JP. The Canadian Home Total Parenteral Nutrition (HTPN) Registry: Vitamin K Supplementation and Bone Mineral Density. JPEN J Parenter Enteral Nutr 2012;36:415-20. [DOI: 10.1177/0148607111431983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
217 Valvano M, Magistroni M, Mancusi A, D'Ascenzo D, Longo S, Stefanelli G, Vernia F, Viscido A, Necozione S, Latella G. The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics. Nutrients 2021;13:323. [PMID: 33499406 DOI: 10.3390/nu13020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Cabr?? E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease: . Current Opinion in Clinical Nutrition and Metabolic Care 2003;6:569-76. [DOI: 10.1097/00075197-200309000-00011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
219 Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S. Inflammation Is The Main Determinant of Low Bone Mineral Density in Pediatric Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2007;13:416-23. [DOI: 10.1002/ibd.20039] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 5.9] [Reference Citation Analysis]
220 Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn’s disease. Scand J Gastroenterol. 2007;42:464-470. [PMID: 17454856 DOI: 10.1080/00365520601010115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
221 Kirchgatterer A, Wenzl HH, Aschl G, Hinterreiter M, Stadler B, Hinterleitner TA, Petritsch W, Knoflach P. Examination, Prevention and Treatment of Osteoporosis in Patients with Inflammatory Bowel Disease: Recommendations and Reality. Acta Med Austriaca 2002;29:120-3. [DOI: 10.1046/j.1563-2571.2002.02018.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
222 Peruzzi B, Teti A. The Physiology and Pathophysiology of the Osteoclast. Clinic Rev Bone Miner Metab 2012;10:71-97. [DOI: 10.1007/s12018-011-9086-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
223 Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol. 2003;98:1797-1801. [PMID: 12907335 DOI: 10.1111/j.1572-0241.2003.07590.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
224 Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122:599-604. [PMID: 19559158 DOI: 10.1016/j.amjmed.2009.01.022] [Cited by in Crossref: 157] [Cited by in F6Publishing: 140] [Article Influence: 12.1] [Reference Citation Analysis]
225 de Jong DJ, Mannaerts L, van Rossum LG, Corstens FH, Naber AH. Longitudinal study of bone mineral density in patients with Crohn's disease. Dig Dis Sci 2003;48:1355-9. [PMID: 12870795 DOI: 10.1023/a:1024171529000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
226 Targownik LE, Leslie WD, Carr R, Clara I, Miller N, Rogala L, Graff LA, Walker JR, Bernstein CN. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int. 2012;91:356-363. [PMID: 22983212 DOI: 10.1007/s00223-012-9650-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
227 Sun JY, Zhang H, Zhang Y, Wang L, Sun BL, Gao F, Liu G. Impact of serum calcium levels on total body bone mineral density: A mendelian randomization study in five age strata. Clin Nutr 2021;40:2726-33. [PMID: 33933738 DOI: 10.1016/j.clnu.2021.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
228 McCabe LR, Parameswaran N. Advances in Probiotic Regulation of Bone and Mineral Metabolism. Calcif Tissue Int 2018;102:480-8. [PMID: 29453726 DOI: 10.1007/s00223-018-0403-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 7.8] [Reference Citation Analysis]
229 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
230 Gordon CM. Bone loss in children with Crohn disease: Evidence of “osteoimmune” alterations. The Journal of Pediatrics 2006;148:429-32. [DOI: 10.1016/j.jpeds.2006.01.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
231 Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut. 2000;46:176-181. [PMID: 10644310 DOI: 10.1136/gut.46.2.176] [Cited by in Crossref: 128] [Cited by in F6Publishing: 116] [Article Influence: 5.8] [Reference Citation Analysis]
232 Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-823. [PMID: 12003413 DOI: 10.1111/j.1572-0241.2002.05596.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 84] [Article Influence: 4.9] [Reference Citation Analysis]
233 Lev-Tzion R, Ben-Moshe T, Abitbol G, Ledder O, Peleg S, Millman P, Shaoul R, Kori M, Assa A, Cohen S, Strich D, Revel-Vilk S, Tiomkin M, Levine A, Sigall Boneh R, Turner D. The Effect of Nutritional Therapy on Bone Mineral Density and Bone Metabolism in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:877-82. [PMID: 33587407 DOI: 10.1097/MPG.0000000000003073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Lai JC, Shoback DM, Zipperstein J, Lizaola B, Tseng S, Terrault NA. Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci 2015;60:1813-9. [PMID: 25563723 DOI: 10.1007/s10620-014-3507-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
235 Adachi JD, Rostom A. Metabolic Bone Disease in Adults with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1999;5:200-11. [DOI: 10.1097/00054725-199908000-00009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
236 Aghdassi E, Wendland BE, Stapleton M, Raman M, Allard JP. Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. J Am Diet Assoc 2007;107:1575-80. [PMID: 17761234 DOI: 10.1016/j.jada.2007.06.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]